BACKGROUND: Tight junctions are an essential component of intestinal epithelial barriers. Claudin-1, occludin, and ZO-1 are the components of tight junction. The purpose of this study was to investigate whether irinotecan induces bacterial translocation in rats, and thus elucidate the relationship between tight junction and bacterial translocation. METHODS: Ten rats were divided into two groups: Five were treated with irinotecan and five were not treated with irinotecan, the control group. Irinotecan treated rats were administrated irinotecan 250 mg/kg intraperitoneally on days designated 0 and 1, were then killed at 48 h after treatment, and tissues were collected for analysis. Controls were treated with a saline solution. RESULTS: In eighty percent of irinotecan treated rats, bacteria were detected in the mesenteric lymph node or spleen. Large intestinal resistance of the rats was decreased. On the contrary, small intestinal resistance increased. Claudin-1 protein expression of both the small and large intestine decreased (P < 0.05), occludin protein expression of the small intestine decreased (P < 0.05), and occludin protein expression of the large intestine had decreasing tendency (P = 0.07) in irinotecan treated rats. In irinotecan treated rats, claudin-1 mRNA of the small intestine decreased (P < 0.05), claudin-1 mRNA of large intestine had a tendency to decrease (P = 0.05), occludin mRNA of both small and large intestine decreased (P < 0.05). CONCLUSIONS: Irinotecan injures claudin-1 and occludin. It causes disorders in the intestinal epithelial barrier and induces bacterial translocation. Copyright Â
BACKGROUND: Tight junctions are an essential component of intestinal epithelial barriers. Claudin-1, occludin, and ZO-1 are the components of tight junction. The purpose of this study was to investigate whether irinotecan induces bacterial translocation in rats, and thus elucidate the relationship between tight junction and bacterial translocation. METHODS: Ten rats were divided into two groups: Five were treated with irinotecan and five were not treated with irinotecan, the control group. Irinotecan treated rats were administrated irinotecan 250 mg/kg intraperitoneally on days designated 0 and 1, were then killed at 48 h after treatment, and tissues were collected for analysis. Controls were treated with a saline solution. RESULTS: In eighty percent of irinotecan treated rats, bacteria were detected in the mesenteric lymph node or spleen. Large intestinal resistance of the rats was decreased. On the contrary, small intestinal resistance increased. Claudin-1 protein expression of both the small and large intestine decreased (P < 0.05), occludin protein expression of the small intestine decreased (P < 0.05), and occludin protein expression of the large intestine had decreasing tendency (P = 0.07) in irinotecan treated rats. In irinotecan treated rats, claudin-1 mRNA of the small intestine decreased (P < 0.05), claudin-1 mRNA of large intestine had a tendency to decrease (P = 0.05), occludin mRNA of both small and large intestine decreased (P < 0.05). CONCLUSIONS:Irinotecan injures claudin-1 and occludin. It causes disorders in the intestinal epithelial barrier and induces bacterial translocation. Copyright Â
Authors: Barbara Vanhoecke; Emma Bateman; Bronwen Mayo; Eline Vanlancker; Andrea Stringer; Daniel Thorpe; Dorothy Keefe Journal: Exp Biol Med (Maywood) Date: 2015-05-12
Authors: Hannah R Wardill; Joanne M Bowen; Noor Al-Dasooqi; Masooma Sultani; Emma Bateman; Romany Stansborough; Joseph Shirren; Rachel J Gibson Journal: Cancer Biol Ther Date: 2013-12-06 Impact factor: 4.742
Authors: R C P Lima-Júnior; H C Freitas; D V T Wong; C W S Wanderley; L G Nunes; L L Leite; S P Miranda; M H L P Souza; G A C Brito; P J C Magalhães; M M Teixeira; F Q Cunha; R A Ribeiro Journal: Br J Pharmacol Date: 2014-05 Impact factor: 8.739
Authors: Hannah R Wardill; Richard M Logan; Joanne M Bowen; Ysabella Z A Van Sebille; Rachel J Gibson Journal: Support Care Cancer Date: 2015-10-06 Impact factor: 3.603
Authors: Xiaoxi B Lin; Levinus A Dieleman; Ali Ketabi; Ilona Bibova; Michael B Sawyer; Hongyu Xue; Catherine J Field; Vickie E Baracos; Michael G Gänzle Journal: PLoS One Date: 2012-07-26 Impact factor: 3.240